Supriya Srivastava
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Supriya Srivastava has a total of 315 co-authors. Here are the top co-authors by number of shared publications:
- Patrick Tan
Cancer and Stem Cell Biology Program, Duke–NUS Graduate Medical School, Singapore, Singapore
27 shared publications - Angie Tan
Program in Cancer and Stem Cell Biology, Duke-NUS Medical School, Singapore, Singapore
26 shared publications - Ming Teh
National University Hospital 13 Department of Pathology Singapore, Singapore
26 shared publications - Takeshi Hagihara
Program in Cancer and Stem Cell Biology, Duke-NUS Medical School, Singapore, Singapore
26 shared publications - Craig Ryan Cecil Joseph
Agency for Science, Technology and Research (A*STAR) 14 Integrated Central Operations and Research Enablers Singapore, Singapore
23 shared publications - Haoran Ma
Duke-NUS Medical School 3 Program in Cancer and Stem Cell Biology Singapore, Singapore
23 shared publications
Latest Publications
- Open Access
- 2 November 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figures S1-S5 from Spatial Organization of Tumor-Infiltrating B Cells Informs Immune Checkpoint Inhibitor Response in Claudin 18.2–Expressing Gastric Cancer
Figure S1: Quality-control parameters and sensitivity analyses of CLDN18.2 microenvironmental and pathway changes Figure S2: Additional sensitivity survival analyses of the YCC cohort and CheckMate 649 trial Figure S3: Features of cellular neighbourhoods and correlation with progression-free survival Figure S4: Supplementary analyses to digital spatial profiling Figure S5: B/plasma cell enrichment scores across the tumor-stroma interface
- 2 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures S1-S5 from Spatial Organization of Tumor-Infiltrating B Cells Informs Immune Checkpoint Inhibitor Response in Claudin 18.2–Expressing Gastric Cancer
Figure S1: Quality-control parameters and sensitivity analyses of CLDN18.2 microenvironmental and pathway changes Figure S2: Additional sensitivity survival analyses of the YCC cohort and CheckMate 649 trial Figure S3: Features of cellular neighbourhoods and correlation with progression-free survival Figure S4: Supplementary analyses to digital spatial profiling Figure S5: B/plasma cell enrichment scores across the tumor-stroma interface
- Open Access
- 2 November 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Tables 1-4 from Spatial Organization of Tumor-Infiltrating B Cells Informs Immune Checkpoint Inhibitor Response in Claudin 18.2–Expressing Gastric Cancer
Supplementary Tables 1-4 from Spatial Organization of Tumor-Infiltrating B Cells Informs Immune Checkpoint Inhibitor Response in Claudin 18.2–Expressing Gastric Cancer
- 2 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Tables 1-4 from Spatial Organization of Tumor-Infiltrating B Cells Informs Immune Checkpoint Inhibitor Response in Claudin 18.2–Expressing Gastric Cancer
Supplementary Tables 1-4 from Spatial Organization of Tumor-Infiltrating B Cells Informs Immune Checkpoint Inhibitor Response in Claudin 18.2–Expressing Gastric Cancer
- Open Access
- 7 August 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 32 (21) , 4922-4935
Spatial Organization of Tumor-Infiltrating B Cells Informs Immune Checkpoint Inhibitor Response in Claudin 18.2–Expressing Gastric Cancer
Purpose: Claudin 18.2 (CLDN18.2), a tight junction protein normally expressed in the gastric epithelium and rendered accessible during malignant transformation, has emerged as a key therapeutic target. Here, we seek to characterize the immune microenvironment of CLDN18.2-expressing gastric cancer and identify immune features associated with CLDN18.2 expression status. Experimental Design: Tumor-immune features were profiled in 103 patients with HER2-neg/low advanced gastric cancer treated with first-line immune checkpoint inhibitor (ICI) using multiplex immunohistochemistry [7,423,483 cells across 2,315 regions of interest (ROI)]. The findings were validated in five published whole-transcriptome sequencing/microarray cohorts (1,521 samples), including the landmark CheckMate 649 phase III trial. Spatial immune architecture was assessed by cellular neighborhood analysis. Digital spatial profiling (DSP) was performed on 480 ROIs from a CLDN18.2-annotated tissue microarray (75 patients). Results: CLDN18.2high tumors showed reproducible enrichment of humoral pathways, with higher CD20+ B-cell density and enrichment of B-cell/plasma-cell signatures. CLDN18.2 status alone was not associated with response or survival on first-line ICI therapy; in CLDN18.2low tumors, B-cell enrichment was associated with ICI benefit, unlike CLDN18.2high tumors. Spatial analyses indicated that CLDN18.2high tumors preferentially harbored tumor-infiltrating B cells, rather than tertiary lymphoid structure/lymphoid aggregate–like neighborhoods, and this tumor-compartment localization was associated with diminished ICI benefit. DSP confirmed that CD20+ B-cell enrichment was most pronounced within tumor regions, alongside compartment-specific activation of humoral and extrafollicular response programs and interferon-associated and remodeling signatures. Conclusions: CLDN18.2high gastric cancer exhibits a humoral-enriched microenvironment with increased tumor-infiltrating B cells and spatial immune organization associated with reduced ICI benefit. Spatial and humoral-state biomarkers may inform ongoing CLDN18.2-directed combination trials.
- 7 August 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 32 (21) , 4922-4935
Open AccessSpatial Organization of Tumor-Infiltrating B Cells Informs Immune Checkpoint Inhibitor Response in Claudin 18.2–Expressing Gastric Cancer
Purpose: Claudin 18.2 (CLDN18.2), a tight junction protein normally expressed in the gastric epithelium and rendered accessible during malignant transformation, has emerged as a key therapeutic target. Here, we seek to characterize the immune microenvironment of CLDN18.2-expressing gastric cancer and identify immune features associated with CLDN18.2 expression status. Experimental Design: Tumor-immune features were profiled in 103 patients with HER2-neg/low advanced gastric cancer treated with first-line immune checkpoint inhibitor (ICI) using multiplex immunohistochemistry [7,423,483 cells across 2,315 regions of interest (ROI)]. The findings were validated in five published whole-transcriptome sequencing/microarray cohorts (1,521 samples), including the landmark CheckMate 649 phase III trial. Spatial immune architecture was assessed by cellular neighborhood analysis. Digital spatial profiling (DSP) was performed on 480 ROIs from a CLDN18.2-annotated tissue microarray (75 patients). Results: CLDN18.2high tumors showed reproducible enrichment of humoral pathways, with higher CD20+ B-cell density and enrichment of B-cell/plasma-cell signatures. CLDN18.2 status alone was not associated with response or survival on first-line ICI therapy; in CLDN18.2low tumors, B-cell enrichment was associated with ICI benefit, unlike CLDN18.2high tumors. Spatial analyses indicated that CLDN18.2high tumors preferentially harbored tumor-infiltrating B cells, rather than tertiary lymphoid structure/lymphoid aggregate–like neighborhoods, and this tumor-compartment localization was associated with diminished ICI benefit. DSP confirmed that CD20+ B-cell enrichment was most pronounced within tumor regions, alongside compartment-specific activation of humoral and extrafollicular response programs and interferon-associated and remodeling signatures. Conclusions: CLDN18.2high gastric cancer exhibits a humoral-enriched microenvironment with increased tumor-infiltrating B cells and spatial immune organization associated with reduced ICI benefit. Spatial and humoral-state biomarkers may inform ongoing CLDN18.2-directed combination trials.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1-9 from Spatially Resolved Tumor Ecosystems and Cell States in Gastric Adenocarcinoma Progression and Evolution
(1) Supplementary Figure 1 shows morphologies of different ROI categories and their representative genes, pathways and similarities with paired scRNA-seq data. (2) Supplementary Figure 2 shows validation of findings from the discovery GeoMx DSP cohort in the whole-section GeoMx DSP cohort and also the TMA GeoMx DSP cohort. (3) Supplementary Figure 3 shows experiments validating that intratumor G1/G2 subregion expression is tumor-intrinsic using multiplexed IHC, Stereoseq spatial transcriptomics, and in vitro Stereoseq drug treatment profiling. (4) Supplementary Figure 4 shows expression of individual immune checkpoints, chemokines, cytokines, molecular signatures (immune exhaustion, intracellular signaling) and emerging therapeutic targets in G1 and G2 subregions in the discovery and validation cohort. (5) Supplementary Figure 5 shows experiments validating that G2 RNA-ITH subregions have higher CNV burdens than G1 subregions using signature scores, CNV calling from scRNA-seq, and validation using WES and Stereoseq data. (6) Supplementary Figure 6 shows phylogenetic analysis and trajectory analysis of scRNA-seq tumor subgroups using various methods. (7) Supplementary Figure 7 shows survival analysis and multi-variate analysis validating that internal diaspora GC is associated with worse prognosis in various cohorts. (8) Supplementary Figure 8 shows functional validation experiments for the potential G2 markers SOX9, AGR2 and TSPAN8 using CellOracle, RNAi and CRISPR knock out assays. (9) Supplementary Figure 9 shows typical pathways, markers and cell types for tumor-stroma interface ROIs.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1-9 from Spatially Resolved Tumor Ecosystems and Cell States in Gastric Adenocarcinoma Progression and Evolution
(1) Supplementary Figure 1 shows morphologies of different ROI categories and their representative genes, pathways and similarities with paired scRNA-seq data. (2) Supplementary Figure 2 shows validation of findings from the discovery GeoMx DSP cohort in the whole-section GeoMx DSP cohort and also the TMA GeoMx DSP cohort. (3) Supplementary Figure 3 shows experiments validating that intratumor G1/G2 subregion expression is tumor-intrinsic using multiplexed IHC, Stereoseq spatial transcriptomics, and in vitro Stereoseq drug treatment profiling. (4) Supplementary Figure 4 shows expression of individual immune checkpoints, chemokines, cytokines, molecular signatures (immune exhaustion, intracellular signaling) and emerging therapeutic targets in G1 and G2 subregions in the discovery and validation cohort. (5) Supplementary Figure 5 shows experiments validating that G2 RNA-ITH subregions have higher CNV burdens than G1 subregions using signature scores, CNV calling from scRNA-seq, and validation using WES and Stereoseq data. (6) Supplementary Figure 6 shows phylogenetic analysis and trajectory analysis of scRNA-seq tumor subgroups using various methods. (7) Supplementary Figure 7 shows survival analysis and multi-variate analysis validating that internal diaspora GC is associated with worse prognosis in various cohorts. (8) Supplementary Figure 8 shows functional validation experiments for the potential G2 markers SOX9, AGR2 and TSPAN8 using CellOracle, RNAi and CRISPR knock out assays. (9) Supplementary Figure 9 shows typical pathways, markers and cell types for tumor-stroma interface ROIs.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1-8 from Spatially Resolved Tumor Ecosystems and Cell States in Gastric Adenocarcinoma Progression and Evolution
(1) Supplementary Table 1 shows GeoMx DSP ROI and scRNA-seq characteristics of samples profiled; (2) Supplementary Table 2 shows clinical characteristics of GeoMx DSP ROI and scRNA-seq samples profiled; (3) Supplementary Table 3A shows consistency between before and after batch effect removal on top enriched pathways in various ROI categories, 3B shows consistency between before and after batch effect removal on G1 and G2 labels on Tumor ROIs; (4) Supplementary Table 4 shows Silhouette scores of using different number of clusters in Tumor ROI hierarchical clustering; (5) Supplementary Table 5 shows detailed information of GeoMx ROIs in the TMA cohort; (6) Supplementary Table 6 shows top DEGs for endothelial cell subtypes (Endo1-Endo3); (7) Supplementary Table 7 shows top DEGs for macrophage cell subtypes (TAM1-TAM6); (8) Supplementary Table 8 shows top DEGs for fibroblast cell subtypes (Fib1-Fib4).
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1-8 from Spatially Resolved Tumor Ecosystems and Cell States in Gastric Adenocarcinoma Progression and Evolution
(1) Supplementary Table 1 shows GeoMx DSP ROI and scRNA-seq characteristics of samples profiled; (2) Supplementary Table 2 shows clinical characteristics of GeoMx DSP ROI and scRNA-seq samples profiled; (3) Supplementary Table 3A shows consistency between before and after batch effect removal on top enriched pathways in various ROI categories, 3B shows consistency between before and after batch effect removal on G1 and G2 labels on Tumor ROIs; (4) Supplementary Table 4 shows Silhouette scores of using different number of clusters in Tumor ROI hierarchical clustering; (5) Supplementary Table 5 shows detailed information of GeoMx ROIs in the TMA cohort; (6) Supplementary Table 6 shows top DEGs for endothelial cell subtypes (Endo1-Endo3); (7) Supplementary Table 7 shows top DEGs for macrophage cell subtypes (TAM1-TAM6); (8) Supplementary Table 8 shows top DEGs for fibroblast cell subtypes (Fib1-Fib4).
- Open Access
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 - S7 from Mutational Signatures and Clonal Hematopoiesis in Intestinal Metaplasia across Countries with Varying Stomach Cancer Incidence
Supplementary Figure S1 shows differential sensitivity of intestinal metaplasia (IM) and normal gastric organoids to pyrvinium and pathway inhibitors, highlighting reduced ERK phosphorylation and selective growth suppression of IM organoids. Supplementary Figure S2 depicts clonal structures in IM samples using SciClone analysis and the effects of DCA-induced oxidative and DNA damage responses in gastric organoids. Supplementary Figure S3 illustrates global DNA methylation alterations in early gastric cancer, including PCA/clustering results, subtype-specific methylation patterns, and associations with replication timing and mutational signatures. Supplementary Figure S4 shows shared germline variant profiles among IM samples from six countries, with UpSet plots and pairwise SNP comparisons illustrating inter-population genomic overlap. Supplementary Figure S5 demonstrates risk stratification for early gastric neoplasia among IM patients using combined clinical and genomic predictors, including ROC and PR curve analyses. Supplementary Figure S6 presents histologic, immunohistochemical, and FISH validation of bacterial presence in gastric cancer tissues, confirming localization of Streptococcus and S. anginosus within tumor regions. Supplementary Figure S7 displays spatial mapping of bacterial reads in gastric cancer tissues, showing host cell-state organization and bacterial localization inferred from Stereopy analysis.
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 - S7 from Mutational Signatures and Clonal Hematopoiesis in Intestinal Metaplasia across Countries with Varying Stomach Cancer Incidence
Supplementary Figure S1 shows differential sensitivity of intestinal metaplasia (IM) and normal gastric organoids to pyrvinium and pathway inhibitors, highlighting reduced ERK phosphorylation and selective growth suppression of IM organoids. Supplementary Figure S2 depicts clonal structures in IM samples using SciClone analysis and the effects of DCA-induced oxidative and DNA damage responses in gastric organoids. Supplementary Figure S3 illustrates global DNA methylation alterations in early gastric cancer, including PCA/clustering results, subtype-specific methylation patterns, and associations with replication timing and mutational signatures. Supplementary Figure S4 shows shared germline variant profiles among IM samples from six countries, with UpSet plots and pairwise SNP comparisons illustrating inter-population genomic overlap. Supplementary Figure S5 demonstrates risk stratification for early gastric neoplasia among IM patients using combined clinical and genomic predictors, including ROC and PR curve analyses. Supplementary Figure S6 presents histologic, immunohistochemical, and FISH validation of bacterial presence in gastric cancer tissues, confirming localization of Streptococcus and S. anginosus within tumor regions. Supplementary Figure S7 displays spatial mapping of bacterial reads in gastric cancer tissues, showing host cell-state organization and bacterial localization inferred from Stereopy analysis.
- Open Access
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Tables S1-S14 from Mutational Signatures and Clonal Hematopoiesis in Intestinal Metaplasia across Countries with Varying Stomach Cancer Incidence
Supplementary Table S1 details all IM and control samples with associated profiling platforms, including targeted DNA sequencing, WGS, single-cell RNA-seq, bulk RNA-seq, shotgun metagenomics, EM-seq, and Stereo-seq datasets. Supplementary Table S2 summarizes major genomic and molecular findings across different countries and ancestral backgrounds. Supplementary Table S3 lists significantly mutated genes identified in non-hypermutated intestinal metaplasia samples. Supplementary Table S4 shows pathways up-regulated in intestinal lineage cells exhibiting high KRAS/ERK expression. Supplementary Table S5 provides a catalog of established IM and normal gastric organoid lines with relevant metadata. Supplementary Table S6 reports Hallmark and GO pathway enrichment analyses comparing KRAS/MAPK-mutated versus wild-type IM, and severe versus mild IM organoids. Supplementary Table S7 displays country- and risk-group-specific proportions of SBS mutational signatures derived from targeted panel sequencing. Supplementary Table S8 shows correlations between mutational signature exposures and patient age in IM samples, including significance from Pearson’s and Spearman’s tests with and without outliers. Supplementary Table S9 lists germline variants occurring in known somatic driver genes among IM patients. Supplementary Table S10 summarizes univariate and multivariate logistic regression analyses linking clinical and molecular risk factors to dysplasia and early gastric neoplasia. Supplementary Table S11 shows associations between bacterial genera abundance and PIGR mutational status in IM samples. Supplementary Table S12 profiles the composition of the oral microbiome from saliva samples of IM patients. Supplementary Table S13 lists Seahorse mitochondrial stress test instrument parameters and assay conditions. Supplementary Table S14 provides Seahorse mitochondrial stress test settings specific to DCA treatment experiments.
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Tables S1-S14 from Mutational Signatures and Clonal Hematopoiesis in Intestinal Metaplasia across Countries with Varying Stomach Cancer Incidence
Supplementary Table S1 details all IM and control samples with associated profiling platforms, including targeted DNA sequencing, WGS, single-cell RNA-seq, bulk RNA-seq, shotgun metagenomics, EM-seq, and Stereo-seq datasets. Supplementary Table S2 summarizes major genomic and molecular findings across different countries and ancestral backgrounds. Supplementary Table S3 lists significantly mutated genes identified in non-hypermutated intestinal metaplasia samples. Supplementary Table S4 shows pathways up-regulated in intestinal lineage cells exhibiting high KRAS/ERK expression. Supplementary Table S5 provides a catalog of established IM and normal gastric organoid lines with relevant metadata. Supplementary Table S6 reports Hallmark and GO pathway enrichment analyses comparing KRAS/MAPK-mutated versus wild-type IM, and severe versus mild IM organoids. Supplementary Table S7 displays country- and risk-group-specific proportions of SBS mutational signatures derived from targeted panel sequencing. Supplementary Table S8 shows correlations between mutational signature exposures and patient age in IM samples, including significance from Pearson’s and Spearman’s tests with and without outliers. Supplementary Table S9 lists germline variants occurring in known somatic driver genes among IM patients. Supplementary Table S10 summarizes univariate and multivariate logistic regression analyses linking clinical and molecular risk factors to dysplasia and early gastric neoplasia. Supplementary Table S11 shows associations between bacterial genera abundance and PIGR mutational status in IM samples. Supplementary Table S12 profiles the composition of the oral microbiome from saliva samples of IM patients. Supplementary Table S13 lists Seahorse mitochondrial stress test instrument parameters and assay conditions. Supplementary Table S14 provides Seahorse mitochondrial stress test settings specific to DCA treatment experiments.
- Open Access
- 14 January 2026
- Published by American Association for Cancer Research (AACR) in Cancer Discovery
- Vol. 16 (3) , 497-520
Mutational Signatures and Clonal Hematopoiesis in Intestinal Metaplasia across Countries with Varying Stomach Cancer Incidence
Intestinal metaplasia (IM) is a premalignant condition associated with increased risk of gastric cancer—a deadly malignancy with varying geographic incidence. High-depth targeted sequencing of more than 1,500 IM samples from six countries identified 47 significantly mutated genes, including driver genes associated with high-risk populations and worse prognosis (ARID1A), KRAS/MAPK signaling (KRAS, BRAF, MAP2K1, MAP3K1, and MAP2K4), and altered mucosal immunity (PIGR). IM whole-genome sequencing and DNA methylation analysis revealed SBS17 as a specific mutational signature separating IMs from normal gastric tissues, associated with late DNA replication, genomic hypomethylation, and tobacco exposure. Beyond epithelial-derived somatic mutations, we observed elevated clonal hematopoiesis (CH) in patients with IM associated with age, smoking, and enhanced risk of progressing to gastric cancer. Patients with CH expansions exhibited co-occurring IM PIGR truncating mutations and greater colonization of the IM microenvironment by orally derived bacteria, suggesting that CH may promote IM progression by modulating host–microbe mucosal immunity. Significance: This international study identifies recurrent IM driver genes, IM-specific mutational signatures, and alterations in IM-associated immune landscapes and microbiomes. Our results highlight a role for nonepithelial somatic alterations (CH) in IM progression to gastric cancer, offering new translational opportunities for early cancer detection and interception.
- 14 January 2026
- Published by American Association for Cancer Research (AACR) in Cancer Discovery
- Vol. 16 (3) , 497-520
Open AccessMutational Signatures and Clonal Hematopoiesis in Intestinal Metaplasia across Countries with Varying Stomach Cancer Incidence
Intestinal metaplasia (IM) is a premalignant condition associated with increased risk of gastric cancer—a deadly malignancy with varying geographic incidence. High-depth targeted sequencing of more than 1,500 IM samples from six countries identified 47 significantly mutated genes, including driver genes associated with high-risk populations and worse prognosis (ARID1A), KRAS/MAPK signaling (KRAS, BRAF, MAP2K1, MAP3K1, and MAP2K4), and altered mucosal immunity (PIGR). IM whole-genome sequencing and DNA methylation analysis revealed SBS17 as a specific mutational signature separating IMs from normal gastric tissues, associated with late DNA replication, genomic hypomethylation, and tobacco exposure. Beyond epithelial-derived somatic mutations, we observed elevated clonal hematopoiesis (CH) in patients with IM associated with age, smoking, and enhanced risk of progressing to gastric cancer. Patients with CH expansions exhibited co-occurring IM PIGR truncating mutations and greater colonization of the IM microenvironment by orally derived bacteria, suggesting that CH may promote IM progression by modulating host–microbe mucosal immunity. Significance: This international study identifies recurrent IM driver genes, IM-specific mutational signatures, and alterations in IM-associated immune landscapes and microbiomes. Our results highlight a role for nonepithelial somatic alterations (CH) in IM progression to gastric cancer, offering new translational opportunities for early cancer detection and interception.
- Open Access
- 13 June 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 4 from Spatial Heterogeneity, Stromal Phenotypes, and Therapeutic Vulnerabilities in Colorectal Cancer Peritoneal Metastasis
Supplementary Table 4. Comparisons of histological features between SC1 and SC2.
- 13 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 4 from Spatial Heterogeneity, Stromal Phenotypes, and Therapeutic Vulnerabilities in Colorectal Cancer Peritoneal Metastasis
Supplementary Table 4. Comparisons of histological features between SC1 and SC2.
- Open Access
- 13 June 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Methods 1 from Spatial Heterogeneity, Stromal Phenotypes, and Therapeutic Vulnerabilities in Colorectal Cancer Peritoneal Metastasis
Supplementary Methods 1. Supplementary Methods, DNA extraction and whole exome sequencing, Mutation calling and mutational signatures, Whole transcriptome sequencing, Spatial profiling, Methods of A5 Discovery and Validation, Other statistical methods and reproducibility.
- 13 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Methods 1 from Spatial Heterogeneity, Stromal Phenotypes, and Therapeutic Vulnerabilities in Colorectal Cancer Peritoneal Metastasis
Supplementary Methods 1. Supplementary Methods, DNA extraction and whole exome sequencing, Mutation calling and mutational signatures, Whole transcriptome sequencing, Spatial profiling, Methods of A5 Discovery and Validation, Other statistical methods and reproducibility.